Travopine B 2 Eye Drop contains Timolol 5mg/ml + Brimonidine 2mg/ml, a dual-action anti-glaucoma ophthalmic formulation designed for effective reduction of elevated intraocular pressure in patients with glaucoma and ocular hypertension. Its precise combination ensures enhanced and sustained pressure control.
The eye drop works by reducing aqueous humor production via Timolol and decreasing aqueous formation while increasing outflow via Brimonidine, providing comprehensive intraocular pressure management and protecting the optic nerve.
From a franchise perspective, Travopine B 2 Eye Drop is a high-demand combination therapy, widely prescribed in eye hospitals, ophthalmology clinics, and glaucoma care centers, ensuring steady prescriptions, repeat orders, and strong prescriber trust.
Adding Travopine B 2 Eye Drop to your portfolio strengthens the ophthalmic anti-glaucoma combination segment, offering long-term growth, market credibility, and a competitive advantage for PCD pharma franchise partners.
Common side effects may include mild burning or stinging, eye redness, dryness, itching, or blurred vision. Rarely, systemic effects such as fatigue, dizziness, slow heart rate, dry mouth, or drowsiness may occur, particularly in sensitive individuals.
Travopine B 2 Eye Drop is indicated for the management of open-angle glaucoma and ocular hypertension in patients who require combination therapy for adequate intraocular pressure reduction. It should be used under the supervision of an ophthalmologist.
Use Travopine B 2 Eye Drop strictly as prescribed by an ophthalmologist. Avoid contact between the dropper tip and the eye to prevent contamination. Use with caution in patients with respiratory or cardiovascular conditions. Discontinue and consult a doctor immediately if severe eye irritation, breathing difficulty, or vision changes occur.
Store in a cool, dry place below 25 °C. Protect from direct sunlight, keep the bottle tightly closed, and out of reach of children. Do not use beyond the expiry date.